MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)_5d9f1a3a35e88.jpeg e5118797b3f9f89090dce53bb927ab53 e5118797b3f9f89090dce53bb927ab53